We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
Pre-Market: 9:01AM EDT
|Bid||1.17 x 500|
|Ask||1.35 x 2000|
|Day's Range||1.15 - 1.40|
|52 Week Range||0.94 - 3.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Guess?, Inc. (NYSE: GES ) stock gained more than 11 ...
SOUTH SAN FRANCISCO, Calif., March 21, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) announced today that it has entered into a definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni has acquired the European intellectual property related to Probuphine, including the Marketing Authorization Application (MAA) under review by the European Medicines Agency (EMA), and will have the exclusive right to commercialize the Titan supplied Probuphine product in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa (the "Molteni Territory").
MONCTON, New Brunswick, March 19, 2018-- Soricimed Biopharma Inc., a clinical-stage pharmaceutical company discovering and developing targeted cancer therapeutics, is pleased to announce that Marc Rubin, ...
SOUTH SAN FRANCISCO, Calif., Feb. 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced its entry into an amendment to the July 2017 loan agreement with Horizon Technology Finance Corporation. Pursuant to this amendment, Titan will prepay $3 million of the outstanding $7 million principle amount, with an additional $1 million prepayment due on the earlier of (i) Titan's receipt of cash proceeds of at least $5 million from the sale of equity or (ii) May 14, 2018. Titan will also provide Horizon with a lien on its intellectual property, which will be released if Titan receives at least $500,000 in aggregate license revenues from sales of Probuphine® in the U.S. and Canada during any consecutive 12-month period prior to December 31, 2019.
By John Vandermosten, CFA NASDAQ:TTNP Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced on January 22 that it is in discussions with Probuphine license holder Braeburn regarding the disposition of Probuphine. ...
Braeburn's receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application for its injectable buprenorphine product is likely to negatively impact Braeburn's Probuphine marketing activities as it focuses on addressing the CRL. Titan has been in preliminary discussions with Braeburn for the return of U.S. commercialization rights to Probuphine and believes it is now appropriate to seek a new partner that can better focus on a successful commercialization strategy for Probuphine.
The most recent earnings update Titan Pharmaceuticals Inc’s (NASDAQ:TTNP) released in September 2017 signalled that the business finally turned profitable after losses on average over the last few years. Below,Read More...
Titan Pharmaceuticals Inc (NASDAQ:TTNP), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...
People Also Watch
|Symbol||Last Price||Change||% Change|
Vanda Pharmaceuticals Inc.
BioDelivery Sciences Internatio
|2.20||+ 0.10||+ 4.76%|
OncoSec Medical Incorporated
Cyclacel Pharmaceuticals, Inc.
Repros Therapeutics Inc.
Industry : Biotechnology
Full Time Employees : 14
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It is also developing ProNeura-Ropinirole, an implant to provide long-term delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; ProNeura-Triiodothyronine, an implant to provide long-term delivery of triiodothyronine for the treatment of hypothyroidism; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia. The company has a collaboration with Opiant Pharmaceuticals, Inc. to explore development of a novel approach for the prevention of opioid relapse and overdose in individuals with opioid use disorder. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.